Cargando…

Complement Effectors of Inflammation in Cystic Fibrosis Lung Fluid Correlate with Clinical Measures of Disease

In cystic fibrosis (CF), lung damage is mediated by a cycle of obstruction, infection, and inflammation. Here we explored complement inflammatory effectors in CF lung fluid. In this study soluble fractions (sols) from sputum samples of 15 CF patients were assayed for complement effectors and analyze...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sass, Laura A., Hair, Pamela S., Perkins, Amy M., Shah, Tushar A., Krishna, Neel K., Cunnion, Kenji M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671727/ https://www.ncbi.nlm.nih.gov/pubmed/26642048 http://dx.doi.org/10.1371/journal.pone.0144723

Ejemplares similares

Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity
por: Hair, Pamela S., et al.
Publicado: (2017)

Inhibition of Myeloperoxidase Activity in Cystic Fibrosis Sputum by Peptide Inhibitor of Complement C1 (PIC1)
por: Hair, Pamela S., et al.
Publicado: (2017)

Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin
por: Hair, Pamela S., et al.
Publicado: (2017)

Inhibition of Immune Complex Complement Activation and Neutrophil Extracellular Trap Formation by Peptide Inhibitor of Complement C1
por: Hair, Pamela S., et al.
Publicado: (2018)

Inhibition of complement activation, myeloperoxidase, NET formation and oxidant activity by PIC1 peptide variants
por: Hair, Pamela S., et al.
Publicado: (2019)

Classical complement pathway inhibition reduces brain damage in a hypoxic ischemic encephalopathy animal model
por: Kumar, Parvathi, et al.
Publicado: (2021)

Clinical hypothermia temperatures increase complement activation and cell destruction via the classical pathway
por: Shah, Tushar A, et al.
Publicado: (2014)

Peptide Inhibitor of Complement C1 (PIC1) demonstrates antioxidant activity via single electron transport (SET) and hydrogen atom transfer (HAT)
por: Gregory Rivera, Magdielis, et al.
Publicado: (2018)

Hyperglycemia Inhibits Complement-Mediated Immunological Control of S. aureus in a Rat Model of Peritonitis
por: Mauriello, Clifford T., et al.
Publicado: (2014)

Peptide Inhibitor of Complement C1, a Novel Suppressor of Classical Pathway Activation: Mechanistic Studies and Clinical Potential
por: Sharp, Julia A., et al.
Publicado: (2014)

Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease and the Role of the Classical Complement Pathway: A Case Report
por: Hair, Pamela S., et al.
Publicado: (2021)

Complement Activation and STAT4 Expression Are Associated with Early Inflammation in Diabetic Wounds
por: Cunnion, Kenji M., et al.
Publicado: (2017)

Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice
por: Bhutta, Maimoona S., et al.
Publicado: (2021)

Peptide inhibition of neutrophil-mediated injury after in vivo challenge with supernatant of Pseudomonas aeruginosa and immune-complexes
por: Enos, Adrianne, et al.
Publicado: (2021)

Peptide Inhibitor of Complement C1 (PIC1) Rapidly Inhibits Complement Activation after Intravascular Injection in Rats
por: Sharp, Julia A., et al.
Publicado: (2015)

Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus
por: Hair, Pamela S, et al.
Publicado: (2012)

Ceftriaxone-Induced Immune Hemolytic Anemia: In Vitro Reversal with Peptide Inhibitor of Complement C1 (PIC1)
por: Cunnion, Kenji M., et al.
Publicado: (2019)

Role of Molecular Diagnostics in the Management of Infectious Disease Emergencies
por: Krishna, Neel K., et al.
Publicado: (2012)

Staphylococcus aureus Surface Protein SdrE Binds Complement Regulator Factor H as an Immune Evasion Tactic
por: Sharp, Julia A., et al.
Publicado: (2012)

The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy
por: Krishna, Neel K., et al.
Publicado: (2022)

Inflammation in Cystic Fibrosis
Publicado: (1996)

RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial RLS-0071-101
por: Goss, Jessica M., et al.
Publicado: (2023)

Interspecies Metabolic Complementation in Cystic Fibrosis Pathogens via Purine Exchange
por: Al Mahmud, Hafij, et al.
Publicado: (2021)

997. RLS-0071 Improves Survival in a Rat Model of Intestinal Necrosis
por: Cunnion, Kenji, et al.
Publicado: (2021)

Deficient Complement Opsonization Impairs Mycobacterium avium Killing by Neutrophils in Cystic Fibrosis
por: Lenhart-Pendergrass, Patricia M., et al.
Publicado: (2023)

Biomarkers of inflammation in infants with cystic fibrosis
por: Laguna, Theresa A., et al.
Publicado: (2018)

Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?
por: Murphy, Sean V., et al.
Publicado: (2019)

Infection, inflammation and exercise in cystic fibrosis
por: van de Weert-van Leeuwen, Pauline Barbera, et al.
Publicado: (2013)

The Resolution Approach to Cystic Fibrosis Inflammation
por: Recchiuti, Antonio, et al.
Publicado: (2020)

Fungal Infection and Inflammation in Cystic Fibrosis
por: Poore, T. Spencer, et al.
Publicado: (2021)

Mitochondrial Stress Responses and “Mito-Inflammation” in Cystic Fibrosis
por: Patergnani, Simone, et al.
Publicado: (2020)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Severe Cystic Periventricular Leukomalacia in a Premature Infant with Capnocytophaga Sepsis
por: Bass, W. Thomas, et al.
Publicado: (2014)

Incompatible erythrocyte transfusion with lipopolysaccharide induces acute lung injury in a novel rat model
por: Gregory Rivera, Magdielis, et al.
Publicado: (2020)

Peptide inhibition of acute lung injury in a novel two-hit rat model
por: Sampson, Alana C., et al.
Publicado: (2021)

Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
por: Harwood, Kiera H., et al.
Publicado: (2021)

Antiproteases as Therapeutics to Target Inflammation in Cystic Fibrosis
por: Quinn, Derek J, et al.
Publicado: (2010)

Inflammation and Infection in Cystic Fibrosis: Update for the Clinician
por: Petrocheilou, Argyri, et al.
Publicado: (2022)

Update of Faecal Markers of Inflammation in Children with Cystic Fibrosis
por: Lee, Jung M., et al.
Publicado: (2012)

Vitamin D Deficiency in Cystic Fibrosis
por: Hall, William B., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1p0erf9sbd29kk6h5um1e7c1jk